Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 92Breast 21Genitourinary 9Gastrointestinal 8Classical hematology 5Thoracic 3Sarcoma 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 5Multiple Myeloma 3Wilms Tumor 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Sarcoma, Ewing 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 6Paclitaxel 4Cyclophosphamide 4Psychiatric Rehabilitation 3Flow Cytometry 3Filgrastim 3Drug Therapy 3Carboplatin 3valspodar 2trametinib 2sargramostim 2epacadostat 2dabrafenib 2X-Rays 2Specimen Handling 2Nivolumab 2Microarray Analysis 2Methylprednisolone 2Melphalan 2Injections 2Immunologic Techniques 2Gemcitabine 2Dexamethasone 2Dasatinib 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × olaparib × Lymphoid × Clear all
NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

AstraZeneca

Phase 1 Completed
49 enrolled
BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡